Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$5.52 USD
+0.03 (0.55%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $5.52 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.52 USD
+0.03 (0.55%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $5.52 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
Zacks News
New Strong Buy Stocks for November 21st
by Zacks Equity Research
AQST, RBT, HARP, VVI and AVTX have been added to the Zacks Rank #1 (Strong Buy) List on November 21, 2023.
Aquestive Therapeutics (AQST) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Aquestive Therapeutics (AQST) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New Strong Buy Stocks for November 16th
by Zacks Equity Research
IMGN, AQST, BUR, GWRE and VECO have been added to the Zacks Rank #1 (Strong Buy) List on November 16, 2023.
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Aquestive Therapeutics (AQST) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
Aquestive Therapeutics (AQST) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
The latest trading day saw Aquestive Therapeutics (AQST) settling at $1.54, representing a -1.91% change from its previous close.
Aquestive Therapeutics (AQST) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Aquestive Therapeutics (AQST) stood at $1.43, denoting a +1.42% change from the preceding trading day.
Aquestive Therapeutics (AQST) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
Aquestive Therapeutics (AQST) closed at $1.32 in the latest trading session, marking a -0.75% move from the prior day.
Aquestive Therapeutics (AQST) Stock Moves -0.71%: What You Should Know
by Zacks Equity Research
In the latest trading session, Aquestive Therapeutics (AQST) closed at $1.39, marking a -0.71% move from the previous day.
Aquestive Therapeutics (AQST) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Aquestive Therapeutics (AQST) closed at $1.52, marking a -0.65% move from the previous day.
Aquestive (AQST) Up on Reaffirming Anaphylm Development Pathway
by Zacks Equity Research
Aquestive (AQST) stock rises 11.8% as the company intends to begin a pivotal pharmacokinetic study of Anaphylm as an oral epinephrine product candidate in the fourth quarter of 2023.
Aquestive Therapeutics (AQST) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Aquestive Therapeutics (AQST) closed the most recent trading day at $1.62, moving +0.62% from the previous trading session.
Aquestive Therapeutics (AQST) Flat As Market Gains: What You Should Know
by Zacks Equity Research
Aquestive Therapeutics (AQST) closed at $1.66 in the latest trading session, marking no change from the prior day.
Aquestive's (AQST) Libervant Accepted for FDA Review, Stock Up
by Zacks Equity Research
Aquestive (AQST) announces FDA acceptance of a regulatory application seeking approval for Libervant to treat pediatric patients with frequent seizure activity. The stock rises 4.7% in response.
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 9.09% and 23.06%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Aquestive (AQST) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Aquestive's (AQST) second-quarter 2023 revenues are likely to have been driven by rising licensed product revenues.
Aquestive Therapeutics (AQST) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Aquestive Therapeutics (AQST) closed at $1.58 in the latest trading session, marking a -1.25% move from the prior day.
Aquestive Therapeutics (AQST) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Aquestive Therapeutics (AQST) closed the most recent trading day at $1.64, moving +1.86% from the previous trading session.
Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year?
by Zacks Equity Research
Here is how Aquestive Therapeutics (AQST) and HCA Healthcare (HCA) have performed compared to their sector so far this year.
Aquestive Therapeutics (AQST) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Aquestive Therapeutics (AQST) closed at $1.62 in the latest trading session, marking a +0.62% move from the prior day.
Down -31.17% in 4 Weeks, Here's Why Aquestive Therapeutics (AQST) Looks Ripe for a Turnaround
by Zacks Equity Research
Aquestive Therapeutics (AQST) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Are Medical Stocks Lagging Agios Pharmaceuticals (AGIO) This Year?
by Zacks Equity Research
Here is how Agios Pharmaceuticals (AGIO) and Aquestive Therapeutics (AQST) have performed compared to their sector so far this year.
Alpine Immune Sciences, Inc. (ALPN) Soars 5.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Is Anebulo Pharmaceuticals (ANEB) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Anebulo Pharmaceuticals, Inc. (ANEB) and Aquestive Therapeutics (AQST) have performed compared to their sector so far this year.
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Aquestive Therapeutics (AQST) and Corvus Pharmaceuticals (CRVS) have performed compared to their sector so far this year.
Are You Looking for a Top Momentum Pick? Why Aquestive Therapeutics (AQST) is a Great Choice
by Zacks Equity Research
Does Aquestive Therapeutics (AQST) have what it takes to be a top stock pick for momentum investors? Let's find out.